FDA has granted accelerated approval to seven neuroscience NMEs since 2016, none of which are approved in Europe

Plus: vaccines stand out for Sanofi, and updates from Outlook, PTC, Y-mAbs, Ascletis, Agios and more

ICER says report highlights ‘bad apples.’ Industry says it is misleading

With $135M up front, Lilly deal unlocks value from biotech’s ARCUS genome-editing tech

Evrysdi from Genentech, PTC is approved for children and adults, will be priced lower than other SMA drugs